nodes	percent_of_prediction	percent_of_DWPC	metapath
Propylthiouracil—Graves' disease—thyroid cancer	0.865	1	CtDrD
Propylthiouracil—TPO—Thyroxine (Thyroid Hormone) Production—TG—thyroid cancer	0.0227	0.293	CbGpPWpGaD
Propylthiouracil—DIO1—Thyroxine biosynthesis—SLC5A5—thyroid cancer	0.00951	0.123	CbGpPWpGaD
Propylthiouracil—TPO—Thyroxine (Thyroid Hormone) Production—TSHR—thyroid cancer	0.00919	0.118	CbGpPWpGaD
Propylthiouracil—TPO—Thyroxine (Thyroid Hormone) Production—SLC5A5—thyroid cancer	0.00688	0.0886	CbGpPWpGaD
Propylthiouracil—DIO1—Amine-derived hormones—SLC5A5—thyroid cancer	0.00546	0.0704	CbGpPWpGaD
Propylthiouracil—TPO—Thyroxine biosynthesis—SLC5A5—thyroid cancer	0.00546	0.0704	CbGpPWpGaD
Propylthiouracil—DIO1—thyroid gland—thyroid cancer	0.00489	0.325	CbGeAlD
Propylthiouracil—TPO—neck—thyroid cancer	0.00463	0.308	CbGeAlD
Propylthiouracil—DBH—Amine-derived hormones—SLC5A5—thyroid cancer	0.00334	0.043	CbGpPWpGaD
Propylthiouracil—TPO—Amine-derived hormones—SLC5A5—thyroid cancer	0.00314	0.0404	CbGpPWpGaD
Propylthiouracil—Allergic cutaneous angiitis—Sorafenib—thyroid cancer	0.0028	0.0659	CcSEcCtD
Propylthiouracil—TPO—thyroid gland—thyroid cancer	0.0022	0.146	CbGeAlD
Propylthiouracil—Interstitial lung disease—Vandetanib—thyroid cancer	0.00187	0.0439	CcSEcCtD
Propylthiouracil—Interstitial pneumonia—Sorafenib—thyroid cancer	0.00184	0.0433	CcSEcCtD
Propylthiouracil—Leukocytoclastic vasculitis—Sorafenib—thyroid cancer	0.00182	0.0427	CcSEcCtD
Propylthiouracil—Skin ulcer—Vandetanib—thyroid cancer	0.0017	0.0399	CcSEcCtD
Propylthiouracil—TPO—Hematopoietic Stem Cell Differentiation—EPO—thyroid cancer	0.00158	0.0204	CbGpPWpGaD
Propylthiouracil—TPO—Differentiation Pathway—EPO—thyroid cancer	0.00137	0.0176	CbGpPWpGaD
Propylthiouracil—DBH—head—thyroid cancer	0.00128	0.0847	CbGeAlD
Propylthiouracil—Interstitial lung disease—Sorafenib—thyroid cancer	0.00126	0.0296	CcSEcCtD
Propylthiouracil—Pigmentation disorder—Epirubicin—thyroid cancer	0.000987	0.0232	CcSEcCtD
Propylthiouracil—Pigmentation disorder—Doxorubicin—thyroid cancer	0.000913	0.0215	CcSEcCtD
Propylthiouracil—DBH—lymph node—thyroid cancer	0.000893	0.0593	CbGeAlD
Propylthiouracil—Erythema nodosum—Epirubicin—thyroid cancer	0.000762	0.0179	CcSEcCtD
Propylthiouracil—DIO1—Amino acid and derivative metabolism—SLC5A5—thyroid cancer	0.000761	0.00981	CbGpPWpGaD
Propylthiouracil—Hepatic failure—Sorafenib—thyroid cancer	0.00072	0.0169	CcSEcCtD
Propylthiouracil—Erythema nodosum—Doxorubicin—thyroid cancer	0.000705	0.0166	CcSEcCtD
Propylthiouracil—Renal failure acute—Sorafenib—thyroid cancer	0.000701	0.0165	CcSEcCtD
Propylthiouracil—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.000686	0.0161	CcSEcCtD
Propylthiouracil—MPO—head—thyroid cancer	0.000682	0.0453	CbGeAlD
Propylthiouracil—Haemoglobin—Vandetanib—thyroid cancer	0.000667	0.0157	CcSEcCtD
Propylthiouracil—Haemorrhage—Vandetanib—thyroid cancer	0.000663	0.0156	CcSEcCtD
Propylthiouracil—Alopecia—Vandetanib—thyroid cancer	0.000586	0.0138	CcSEcCtD
Propylthiouracil—DIO1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000583	0.00751	CbGpPWpGaD
Propylthiouracil—Dysgeusia—Vandetanib—thyroid cancer	0.000566	0.0133	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—MINPP1—thyroid cancer	0.000504	0.0065	CbGpPWpGaD
Propylthiouracil—Arthralgia—Vandetanib—thyroid cancer	0.000492	0.0116	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000489	0.0115	CcSEcCtD
Propylthiouracil—Jaundice—Sorafenib—thyroid cancer	0.000486	0.0114	CcSEcCtD
Propylthiouracil—MPO—lymph node—thyroid cancer	0.000478	0.0317	CbGeAlD
Propylthiouracil—Oedema—Vandetanib—thyroid cancer	0.000471	0.0111	CcSEcCtD
Propylthiouracil—DBH—Amino acid and derivative metabolism—SLC5A5—thyroid cancer	0.000465	0.00599	CbGpPWpGaD
Propylthiouracil—Thrombocytopenia—Vandetanib—thyroid cancer	0.000462	0.0108	CcSEcCtD
Propylthiouracil—Haemoglobin—Sorafenib—thyroid cancer	0.00045	0.0106	CcSEcCtD
Propylthiouracil—Haemorrhage—Sorafenib—thyroid cancer	0.000448	0.0105	CcSEcCtD
Propylthiouracil—Neuritis—Epirubicin—thyroid cancer	0.000441	0.0104	CcSEcCtD
Propylthiouracil—TPO—Amino acid and derivative metabolism—SLC5A5—thyroid cancer	0.000437	0.00563	CbGpPWpGaD
Propylthiouracil—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000429	0.0101	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—NDUFA13—thyroid cancer	0.000429	0.00553	CbGpPWpGaD
Propylthiouracil—Paraesthesia—Vandetanib—thyroid cancer	0.000423	0.00995	CcSEcCtD
Propylthiouracil—Skin ulcer—Epirubicin—thyroid cancer	0.000423	0.00994	CcSEcCtD
Propylthiouracil—Dyspepsia—Vandetanib—thyroid cancer	0.000415	0.00975	CcSEcCtD
Propylthiouracil—Neuritis—Doxorubicin—thyroid cancer	0.000408	0.00959	CcSEcCtD
Propylthiouracil—Ageusia—Epirubicin—thyroid cancer	0.000407	0.00956	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—CHST14—thyroid cancer	0.000403	0.0052	CbGpPWpGaD
Propylthiouracil—Alopecia—Sorafenib—thyroid cancer	0.000395	0.0093	CcSEcCtD
Propylthiouracil—Skin ulcer—Doxorubicin—thyroid cancer	0.000391	0.0092	CcSEcCtD
Propylthiouracil—Liver injury—Epirubicin—thyroid cancer	0.000391	0.0092	CcSEcCtD
Propylthiouracil—Dysgeusia—Sorafenib—thyroid cancer	0.000382	0.00897	CcSEcCtD
Propylthiouracil—Ageusia—Doxorubicin—thyroid cancer	0.000376	0.00884	CcSEcCtD
Propylthiouracil—Body temperature increased—Vandetanib—thyroid cancer	0.000373	0.00876	CcSEcCtD
Propylthiouracil—Liver injury—Doxorubicin—thyroid cancer	0.000362	0.00851	CcSEcCtD
Propylthiouracil—Leukopenia—Sorafenib—thyroid cancer	0.000349	0.0082	CcSEcCtD
Propylthiouracil—Pruritus—Vandetanib—thyroid cancer	0.000333	0.00784	CcSEcCtD
Propylthiouracil—Arthralgia—Sorafenib—thyroid cancer	0.000332	0.0078	CcSEcCtD
Propylthiouracil—Myalgia—Sorafenib—thyroid cancer	0.000332	0.0078	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—HPGD—thyroid cancer	0.000325	0.00419	CbGpPWpGaD
Propylthiouracil—Thrombocytopenia—Sorafenib—thyroid cancer	0.000311	0.00732	CcSEcCtD
Propylthiouracil—Aplastic anaemia—Epirubicin—thyroid cancer	0.000309	0.00727	CcSEcCtD
Propylthiouracil—DBH—Metabolism—MINPP1—thyroid cancer	0.000308	0.00397	CbGpPWpGaD
Propylthiouracil—Vomiting—Vandetanib—thyroid cancer	0.0003	0.00704	CcSEcCtD
Propylthiouracil—Rash—Vandetanib—thyroid cancer	0.000297	0.00699	CcSEcCtD
Propylthiouracil—Dermatitis—Vandetanib—thyroid cancer	0.000297	0.00698	CcSEcCtD
Propylthiouracil—Headache—Vandetanib—thyroid cancer	0.000295	0.00694	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00029	0.00681	CcSEcCtD
Propylthiouracil—TPO—Metabolism—MINPP1—thyroid cancer	0.00029	0.00373	CbGpPWpGaD
Propylthiouracil—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000286	0.00673	CcSEcCtD
Propylthiouracil—Lymphadenopathy—Epirubicin—thyroid cancer	0.00028	0.00659	CcSEcCtD
Propylthiouracil—Nausea—Vandetanib—thyroid cancer	0.00028	0.00658	CcSEcCtD
Propylthiouracil—Dyspepsia—Sorafenib—thyroid cancer	0.00028	0.00658	CcSEcCtD
Propylthiouracil—Hepatic failure—Epirubicin—thyroid cancer	0.000266	0.00625	CcSEcCtD
Propylthiouracil—DBH—Metabolism—NDUFA13—thyroid cancer	0.000262	0.00338	CbGpPWpGaD
Propylthiouracil—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000259	0.00609	CcSEcCtD
Propylthiouracil—Renal failure acute—Epirubicin—thyroid cancer	0.000259	0.00609	CcSEcCtD
Propylthiouracil—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000253	0.00596	CcSEcCtD
Propylthiouracil—Urticaria—Sorafenib—thyroid cancer	0.000253	0.00594	CcSEcCtD
Propylthiouracil—Body temperature increased—Sorafenib—thyroid cancer	0.000251	0.00591	CcSEcCtD
Propylthiouracil—DBH—Metabolism—CHST14—thyroid cancer	0.000246	0.00318	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—NDUFA13—thyroid cancer	0.000246	0.00318	CbGpPWpGaD
Propylthiouracil—Hepatic failure—Doxorubicin—thyroid cancer	0.000246	0.00579	CcSEcCtD
Propylthiouracil—Renal failure acute—Doxorubicin—thyroid cancer	0.00024	0.00563	CcSEcCtD
Propylthiouracil—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000234	0.00551	CcSEcCtD
Propylthiouracil—TPO—Metabolism—CHST14—thyroid cancer	0.000232	0.00299	CbGpPWpGaD
Propylthiouracil—Pruritus—Sorafenib—thyroid cancer	0.000225	0.00529	CcSEcCtD
Propylthiouracil—MPO—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000218	0.00281	CbGpPWpGaD
Propylthiouracil—MPO—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.00021	0.00271	CbGpPWpGaD
Propylthiouracil—Vomiting—Sorafenib—thyroid cancer	0.000202	0.00475	CcSEcCtD
Propylthiouracil—Rash—Sorafenib—thyroid cancer	0.0002	0.00471	CcSEcCtD
Propylthiouracil—Dermatitis—Sorafenib—thyroid cancer	0.0002	0.00471	CcSEcCtD
Propylthiouracil—Headache—Sorafenib—thyroid cancer	0.000199	0.00468	CcSEcCtD
Propylthiouracil—DBH—Metabolism—HPGD—thyroid cancer	0.000199	0.00256	CbGpPWpGaD
Propylthiouracil—MPO—C-MYB transcription factor network—CCND1—thyroid cancer	0.000197	0.00254	CbGpPWpGaD
Propylthiouracil—Nausea—Sorafenib—thyroid cancer	0.000189	0.00444	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—TPR—thyroid cancer	0.000187	0.00241	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—HPGD—thyroid cancer	0.000187	0.00241	CbGpPWpGaD
Propylthiouracil—Drowsiness—Epirubicin—thyroid cancer	0.000184	0.00433	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—PRKAR1A—thyroid cancer	0.000184	0.00237	CbGpPWpGaD
Propylthiouracil—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000181	0.00425	CcSEcCtD
Propylthiouracil—Jaundice—Epirubicin—thyroid cancer	0.00018	0.00422	CcSEcCtD
Propylthiouracil—Agranulocytosis—Epirubicin—thyroid cancer	0.000172	0.00404	CcSEcCtD
Propylthiouracil—Drowsiness—Doxorubicin—thyroid cancer	0.00017	0.00401	CcSEcCtD
Propylthiouracil—MPO—C-MYB transcription factor network—NRAS—thyroid cancer	0.000169	0.00218	CbGpPWpGaD
Propylthiouracil—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000167	0.00393	CcSEcCtD
Propylthiouracil—Haemoglobin—Epirubicin—thyroid cancer	0.000166	0.00391	CcSEcCtD
Propylthiouracil—Jaundice—Doxorubicin—thyroid cancer	0.000166	0.00391	CcSEcCtD
Propylthiouracil—Haemorrhage—Epirubicin—thyroid cancer	0.000165	0.00389	CcSEcCtD
Propylthiouracil—Hepatitis—Epirubicin—thyroid cancer	0.000165	0.00389	CcSEcCtD
Propylthiouracil—Agranulocytosis—Doxorubicin—thyroid cancer	0.000159	0.00374	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—TP53—thyroid cancer	0.000157	0.00203	CbGpPWpGaD
Propylthiouracil—Haemoglobin—Doxorubicin—thyroid cancer	0.000154	0.00362	CcSEcCtD
Propylthiouracil—Haemorrhage—Doxorubicin—thyroid cancer	0.000153	0.0036	CcSEcCtD
Propylthiouracil—Hepatitis—Doxorubicin—thyroid cancer	0.000153	0.0036	CcSEcCtD
Propylthiouracil—Alopecia—Epirubicin—thyroid cancer	0.000146	0.00344	CcSEcCtD
Propylthiouracil—MPO—C-MYB transcription factor network—KRAS—thyroid cancer	0.000146	0.00188	CbGpPWpGaD
Propylthiouracil—Dysgeusia—Epirubicin—thyroid cancer	0.000141	0.00331	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—SLC5A5—thyroid cancer	0.00014	0.0018	CbGpPWpGaD
Propylthiouracil—Alopecia—Doxorubicin—thyroid cancer	0.000135	0.00318	CcSEcCtD
Propylthiouracil—Dysgeusia—Doxorubicin—thyroid cancer	0.00013	0.00307	CcSEcCtD
Propylthiouracil—Vertigo—Epirubicin—thyroid cancer	0.000129	0.00304	CcSEcCtD
Propylthiouracil—Leukopenia—Epirubicin—thyroid cancer	0.000129	0.00303	CcSEcCtD
Propylthiouracil—MPO—C-MYB transcription factor network—HRAS—thyroid cancer	0.000124	0.0016	CbGpPWpGaD
Propylthiouracil—Myalgia—Epirubicin—thyroid cancer	0.000123	0.00288	CcSEcCtD
Propylthiouracil—Arthralgia—Epirubicin—thyroid cancer	0.000123	0.00288	CcSEcCtD
Propylthiouracil—Vertigo—Doxorubicin—thyroid cancer	0.00012	0.00281	CcSEcCtD
Propylthiouracil—Leukopenia—Doxorubicin—thyroid cancer	0.000119	0.0028	CcSEcCtD
Propylthiouracil—Oedema—Epirubicin—thyroid cancer	0.000118	0.00276	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—RXRA—thyroid cancer	0.000117	0.00151	CbGpPWpGaD
Propylthiouracil—Thrombocytopenia—Epirubicin—thyroid cancer	0.000115	0.0027	CcSEcCtD
Propylthiouracil—DBH—Metabolism—TPR—thyroid cancer	0.000114	0.00147	CbGpPWpGaD
Propylthiouracil—Myalgia—Doxorubicin—thyroid cancer	0.000113	0.00267	CcSEcCtD
Propylthiouracil—Arthralgia—Doxorubicin—thyroid cancer	0.000113	0.00267	CcSEcCtD
Propylthiouracil—DBH—Metabolism—PRKAR1A—thyroid cancer	0.000112	0.00145	CbGpPWpGaD
Propylthiouracil—Oedema—Doxorubicin—thyroid cancer	0.000109	0.00256	CcSEcCtD
Propylthiouracil—TPO—Metabolism—TPR—thyroid cancer	0.000107	0.00138	CbGpPWpGaD
Propylthiouracil—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000107	0.00252	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000106	0.0025	CcSEcCtD
Propylthiouracil—Paraesthesia—Epirubicin—thyroid cancer	0.000106	0.00248	CcSEcCtD
Propylthiouracil—TPO—Metabolism—PRKAR1A—thyroid cancer	0.000105	0.00136	CbGpPWpGaD
Propylthiouracil—Somnolence—Epirubicin—thyroid cancer	0.000104	0.00246	CcSEcCtD
Propylthiouracil—Dyspepsia—Epirubicin—thyroid cancer	0.000103	0.00243	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	9.91e-05	0.00233	CcSEcCtD
Propylthiouracil—Paraesthesia—Doxorubicin—thyroid cancer	9.76e-05	0.00229	CcSEcCtD
Propylthiouracil—Somnolence—Doxorubicin—thyroid cancer	9.67e-05	0.00227	CcSEcCtD
Propylthiouracil—Dyspepsia—Doxorubicin—thyroid cancer	9.57e-05	0.00225	CcSEcCtD
Propylthiouracil—Urticaria—Epirubicin—thyroid cancer	9.34e-05	0.00219	CcSEcCtD
Propylthiouracil—Body temperature increased—Epirubicin—thyroid cancer	9.29e-05	0.00218	CcSEcCtD
Propylthiouracil—Urticaria—Doxorubicin—thyroid cancer	8.64e-05	0.00203	CcSEcCtD
Propylthiouracil—Body temperature increased—Doxorubicin—thyroid cancer	8.6e-05	0.00202	CcSEcCtD
Propylthiouracil—DBH—Metabolism—SLC5A5—thyroid cancer	8.54e-05	0.0011	CbGpPWpGaD
Propylthiouracil—Pruritus—Epirubicin—thyroid cancer	8.31e-05	0.00195	CcSEcCtD
Propylthiouracil—TPO—Metabolism—SLC5A5—thyroid cancer	8.03e-05	0.00103	CbGpPWpGaD
Propylthiouracil—Pruritus—Doxorubicin—thyroid cancer	7.69e-05	0.00181	CcSEcCtD
Propylthiouracil—Vomiting—Epirubicin—thyroid cancer	7.47e-05	0.00176	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—PPARG—thyroid cancer	7.41e-05	0.000956	CbGpPWpGaD
Propylthiouracil—Rash—Epirubicin—thyroid cancer	7.41e-05	0.00174	CcSEcCtD
Propylthiouracil—Dermatitis—Epirubicin—thyroid cancer	7.4e-05	0.00174	CcSEcCtD
Propylthiouracil—Headache—Epirubicin—thyroid cancer	7.36e-05	0.00173	CcSEcCtD
Propylthiouracil—DBH—Metabolism—RXRA—thyroid cancer	7.17e-05	0.000925	CbGpPWpGaD
Propylthiouracil—Nausea—Epirubicin—thyroid cancer	6.98e-05	0.00164	CcSEcCtD
Propylthiouracil—Vomiting—Doxorubicin—thyroid cancer	6.91e-05	0.00162	CcSEcCtD
Propylthiouracil—Rash—Doxorubicin—thyroid cancer	6.86e-05	0.00161	CcSEcCtD
Propylthiouracil—Dermatitis—Doxorubicin—thyroid cancer	6.85e-05	0.00161	CcSEcCtD
Propylthiouracil—Headache—Doxorubicin—thyroid cancer	6.81e-05	0.0016	CcSEcCtD
Propylthiouracil—TPO—Metabolism—RXRA—thyroid cancer	6.74e-05	0.000869	CbGpPWpGaD
Propylthiouracil—Nausea—Doxorubicin—thyroid cancer	6.46e-05	0.00152	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—PTGS2—thyroid cancer	5.83e-05	0.000752	CbGpPWpGaD
Propylthiouracil—DIO1—Metabolism—PTEN—thyroid cancer	5.09e-05	0.000656	CbGpPWpGaD
Propylthiouracil—DBH—Metabolism—PPARG—thyroid cancer	4.53e-05	0.000584	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—PPARG—thyroid cancer	4.26e-05	0.000549	CbGpPWpGaD
Propylthiouracil—DBH—Metabolism—PTGS2—thyroid cancer	3.56e-05	0.000459	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—PTGS2—thyroid cancer	3.35e-05	0.000432	CbGpPWpGaD
Propylthiouracil—DBH—Metabolism—PTEN—thyroid cancer	3.11e-05	0.0004	CbGpPWpGaD
Propylthiouracil—DIO1—Metabolism—AKT1—thyroid cancer	2.93e-05	0.000378	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—PTEN—thyroid cancer	2.92e-05	0.000377	CbGpPWpGaD
Propylthiouracil—DBH—Metabolism—AKT1—thyroid cancer	1.79e-05	0.000231	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—AKT1—thyroid cancer	1.68e-05	0.000217	CbGpPWpGaD
